Zobrazeno 1 - 10
of 55
pro vyhledávání: ''
Autor:
Weiqiang Zhao, Mahmoud Abdel-Rasoul, Desmond M. D’Souza, David P. Carbone, Robert E. Merritt, Dan Jones, Peter J. Kneuertz, Terrance M. Williams, Konstantin Shilo
Publikováno v:
Lung Cancer. 143:60-66
This study aimed to evaluate the prognostic and potential therapeutic value of expanded molecular testing of resected early-stage lung ACA.We analyzed 324 patients who underwent lobectomy and lymphadenectomy for clinical Stage III lung ACA between 20
Autor:
Anas Gazzah, Pilar Garrido, Alexis B. Cortot, Jaafar Bennouna, Melissa Lynne Johnson, Maciej Gil, Haruyasu Murakami, Benjamin Besse
Publikováno v:
Lung Cancer. 142:63-69
Objectives Efficacy and safety of necitumumab when combined with pembrolizumab was assessed in patients with Stage IV non-small cell lung cancer (NSCLC) of squamous and nonsquamous histology, who had progressed after treatment with a platinum-based d
Autor:
Kazuya Shinmura, Yuji Iwashita, Masayuki Tanahashi, Kazuhito Funai, Haruhiko Sugimura, Takafumi Suda, Katsuhiro Yoshimura, Naoki Inui, Hiroshi Niwa, Masato Karayama, Hidetaka Yamada, Akikazu Kawase, Yusuke Inoue, Hiroshi Ogawa, Kazuo Tsuchiya
Publikováno v:
Lung Cancer. 141:21-31
Alterations in the MET gene, such as mutations and high-level amplification, are important drivers of non-small cell lung cancer (NSCLC). The efficacy of immune checkpoint inhibitors (ICIs) in lung cancer with MET abnormalities is unclear. We evaluat
Autor:
Jacob Sands, Geoffrey R. Oxnard, Pasi A. Jänne, Frank C. Kuo, Adrian G. Sacher, Tom C. Nguyen, Lynette M. Sholl, Michael Cheng, Priyanka Shivdasani, Ryan S. Alden
Publikováno v:
Lung Cancer. 140:35-41
Objectives Potentially targetable genomic alterations have been identified in lung squamous cell carcinoma (LUSC), but none have yet translated into effective therapy. We examined potential benefits of next generation sequencing (NGS) in a cohort of
Autor:
Alvin Soon Tiong Lim, Quan Sing Ng, Anantham Devanand, Daniel S.W. Tan, T. Rajasekaran, Eng Huat Tan, Zaw Win Aung, Chee Keong Toh, G. Lai, Chow Wei Too, Tony Kiat-Hon Lim, Aaron C. Tan, Bien Soo Tan, Tina P.T. Koh, Tse Hui Lim, Mei-Kim Ang, Angela Takano, Wan Ling Tan, Shou Yu Poon, Brett Doble, Apoorva Gogna, Amit Jain, Boon-Hean Ong, Ravindran Kanesvaran, Wan-Teck Lim, Gek San Tan
Publikováno v:
Lung Cancer. 139:207-215
Objectives There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsie
Autor:
Masayuki Takeda, Kaoru Tanaka, Kimio Yonesaka, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Takayuki Takahama, Ryoji Kato, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Lung Cancer. 139:28-34
Objectives The T790M secondary mutation of epidermal growth factor receptor gene (EGFR) is the most common mechanism of acquired resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). We investigated the association between
Autor:
Encarnação Teixeira, Sousa Ac, Martins J, Janeiro A, Malveiro S, M. Felizardo, Oliveira Ar, Nogueira F, Maria Carmo-Fonseca, Silveira C
Publikováno v:
Lung Cancer. 139:35-40
Objectives Mutations in the gene that encodes epidermal growth factor receptor (EGFR) are biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR-targeted therapies collectively known as tyrosine kinase inhibitors (TKI
Autor:
Thüsen J.H. von der, Melinda A. Pruis, A-M.C. Dingemans, Willemina R. R. Geurts-Giele, Isabelle C. Meijssen, W. Dinjens, Marthe S. Paats, Hendrikus J. Dubbink, Martijn P. Lolkema, Joachim G.J.V. Aerts
Publikováno v:
Lung Cancer, 140, 46-54. Elsevier Ireland Ltd
Objectives The oncogenic MET exon 14 skipping mutation (METex14del) is described to drive 1.3 %–5.7 % of non-small-cell lung cancer (NSCLC) and multiple studies with cMET inhibitors show promising clinical responses. RNA-based analysis seems most o
Autor:
Tetsuya Sakai, Shingo Matsumoto, Seiji Niho, Yoshitaka Zenke, Masahiro Tsuboi, Keisuke Kirita, Koichi Goto, Genichiro Ishii, Shigeki Umemura, Tomoyuki Naito, Kiyotaka Yoh, Hibiki Udagawa
Publikováno v:
Lung Cancer. 138:35-42
Loss of the chromatin remodeling SWItch/Sucrose Non-fermentable (SWI/SNF) complex is implicated in the pathogenesis of several types of neoplasms. The aim of this study was to examine the clinicopathological features of non-small cell lung cancer (NS
Autor:
Anke Behnke, Denise Treue, Philipp Jurmeister, Leonille Schweizer, Maximilian von Laffert, Claudia Vollbrecht, Nikolaj Frost, Jens-Carsten Rückert, David Horst, Jens Neudecker, Frederick Klauschen, Manfred Dietel, Alexander Arnold, Michael Hummel
Publikováno v:
Lung Cancer. 138:43-51
Objectives We aim to provide a better understanding of the molecular landscape of primary lung adenocarcinomas with intestinal differentiation. Material and Methods Five invasive mucinous adenocarcinomas (IMA) and seven pulmonary enteric adenocarcino